Clinical Trials Logo

Clinical Trial Summary

This study is a phase 3 randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of SAL-0951 in CKD-anemia patients in Non-dialysis, comprising 8 weeks of double-blind treatment period followed by an open-label treatment period, making up a total of 27 weeks.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06016036
Study type Interventional
Source Shenzhen Salubris Pharmaceuticals Co., Ltd.
Contact
Status Completed
Phase Phase 3
Start date December 8, 2020
Completion date February 21, 2022